Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PALMITATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PALMITATE HYDROCHLORIDE.
CLEOCIN PHOSPHATE vs CLINDAMYCIN PALMITATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
Clindamycin palmitate hydrochloride is a prodrug that is hydrolyzed in vivo to clindamycin. Clindamycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking peptide bond formation. It also inhibits the early stages of protein synthesis by interfering with the initiation complex.
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
150-300 mg orally every 6 hours. Maximum dose: 1.8 g/day.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age.
Terminal elimination half-life is approximately 2.4–3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8–10 hours.
Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route.
Approximately 10% of the dose is excreted unchanged in urine; the remainder is eliminated as inactive metabolites via bile (about 30–40%) and feces (about 50–60%). Renal clearance is minor and dosing adjustment is not typically required in renal impairment.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic